Skip to main content
$10.01 -$1.15 (-10.3%)

04:00 PM EDT on 09/17/21

Lumos Pharma Inc (NASDAQ:LUMO)

CAPS Rating: 1 out of 5

Current Price $10.01 Mkt Cap $93.3M
Open $11.16 P/E Ratio 0.00
Prev. Close $10.01 Div. (Yield) $0.00 (0.0%)
Daily Range $9.99 - $11.32 Volume 53,980
52-Wk Range $7.23 - $36.72 Avg. Daily Vol. 88,621

Caps

How do you think NASDAQ:LUMO will perform against the market?

Add Stock to CAPS Watchlist

All Players

41 Outperform
15 Underperform
 

All-Star Players

11 Outperform
6 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:LUMO Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Dennyboy01 (< 20)
Submitted January 13, 2014

This company appears to be on track in developing products to fight cancer and should be a good buyout candidate.

zzlangerhans (99.03)
Submitted April 30, 2013

I laid out the reasons why I think HyperAcute Pancreas will fail here in February: http://caps.fool.com/Pitch/NLNK/6662267/newlinks-most-advanced-clinica.aspxAfter closing my prior underperform for a win I'm back in red and quickly down 12 points.… More

NASDAQ:LUMO VS S&P 500 (SPY)

Fools bullish on NASDAQ:LUMO are also bullish on:

Fools bearish on NASDAQ:LUMO are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about LUMO.

Recs

0
Member Avatar mdriver78 (75.43) Submitted: 3/24/2021 12:04:47 PM : Outperform Start Price: $14.23 NASDAQ:LUMO Score: -42.47

Lumos is focused on the development of a drug, LUM-201, which is designed to treat a rare disease called pediatric growth hormone deficiency (PGHD). PGHD happens in kids whose pituitary glands don’t produce enough growth hormone. They don’t grow as fast (if at all) or tall as a result. The lack of GH retards sexual maturity, and also causes other symptoms like low bone density and high cholesterol.

The treatment for PGHD usually involves daily injections. Lumos, however, has developed a more convenient oral drug that promotes growth hormone secretion by the pituitary gland.

LUM-201 already has been studied in 1,200 patients both young and old and found to be generally well tolerated. LUM-201 may be more effective, too. Lumos presented at the Endocrine Society’s annual meeting this week. The data the company presented at the scientific meeting shows that its drug produces a greater GH response than standard therapies used to treat this condition.

Lumos launched a Phase 2b trial late last year and will launch an additional trial next quarter. Trials will begin to read out by the middle of next year.

The company also plans to expand beyond PGHD to include other parts of the human growth hormone market. This market is estimated to be worth as much as $3.4 billion worldwide.

The company’s market cap is $102 million after yesterday’s sell-off, and the company reports $98.7 million on its books as of its fourth-quarter filing. That figure doesn’t include the $26 million the company received in 2021 for its 60% ownership in developing an Ebola vaccine.

Upon approval, the FDA granted Lumos a priority review voucher for developing the Ebola vaccine. These vouchers allow a developer to accelerate the review period the FDA undertakes for approval. It can be very valuable for a drug company that wants to rush to market first. Lumos was then able to sell the voucher to Merck, which finished its second payment early this year.

If we include that sum, Lumos is actually trading for less than cash. This means the market is valuing its developmental pipeline and other assets at essentially zero despite the fact that the company is targeting an initial market in PGHD potentially worth over $1 billion.

Recs

0
Member Avatar oscillation (75.77) Submitted: 9/21/2018 11:49:15 PM : Outperform Start Price: $2.37 NASDAQ:LUMO Score: +270.64

nev

Recs

0
Member Avatar TMFEBCapital (96.79) Submitted: 4/11/2017 11:06:31 AM : Outperform Start Price: $16.22 NASDAQ:LUMO Score: -127.35

Market was unimpressed by advanced melanoma data relative to peer INCY, however, the data was strong, and it continues to validate IDO-targeting. Additional data later this year from GDC-0919 (with Roche) could expand the market opportunity beyond melanoma to solid tumors. Overall, this is a high risk, high reward stock.

Leaderboard

Find the members with the highest scoring picks in LUMO.

Score Leader

sln

sln (33.69) Score: +486.05

The Score Leader is the player with the highest score across all their picks in LUMO.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
portefeuille2 98.97 4/29/2019 Outperform 5Y $1.63 +514.11% +50.60% +463.52 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. zzlangerhans 99.03 9/20/2018 Outperform 1Y $2.34 +327.78% +50.90% +276.88 0 Comment
mjonesy1985 95.81 10/8/2018 Outperform 3W $2.34 +327.78% +53.99% +273.79 0 Comment
oscillation 75.77 9/24/2018 Outperform 5Y $2.37 +322.36% +51.72% +270.64 1 Comment
rancidlettuce 29.31 9/25/2018 Outperform 5Y $2.48 +303.63% +51.89% +251.74 0 Comment
MFBurritoSquat 71.51 5/2/2012 10/31/2012 Underperform 3M $11.04 -9.33% +215.91% +225.24 0 Comment
goldminingXpert 27.27 5/13/2013 Underperform NS $15.85 -36.85% +170.00% +206.85 0 Comment
joe508mama 29.96 10/16/2014 Underperform 5Y $27.94 -64.17% +138.63% +202.80 0 Comment
DannyMac180 < 20 10/23/2014 Underperform 3M $38.73 -74.15% +127.12% +201.27 0 Comment
CAPSTech 30.80 12/2/2013 Underperform 3M $22.10 -54.70% +144.48% +199.18 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for LUMO.